研究评估分析软件对手术室管制药物管理和药物滥用的影响。

Study to assess the impact of analytics software on operating room controlled substance management and drug diversion.

机构信息

Ochsner Clinic Foundation, New Orleans, LA, and The University of Queensland Medical School-Ochsner Clinical School, New Orleans, LA, USA.

Ochsner Clinic Foundation, New Orleans, LA, USA.

出版信息

Am J Health Syst Pharm. 2024 May 24;81(11):e322-e328. doi: 10.1093/ajhp/zxae013.

DOI:10.1093/ajhp/zxae013

PMID:38456350

Abstract

PURPOSE

This study investigated the impact of an advanced analytics software solution in the operating room (OR) on tracking and evaluating controlled substance discrepancies. The authors hypothesized that the software would increase identification of these discrepancies and improve the efficiency of the preexisting manual process.

METHODS

In this evaluation comparing data from before to after implementation of the software, data were collected using the preexisting manual process for 50 days before implementation, followed by a 25-day period for acclimation to the new software, and ending with a 49-day postimplementation review period. Data collected included the total number of medication discrepancies, time required for discrepancy review and reconciliation by an OR analyst, types of discrepancies, and number of discrepancies leading to provider audits.

RESULTS

Before implementation of the analytics software, there were 7,635 OR cases with a total of 674 charting discrepancies (8.83 discrepancies per 100 total OR cases) discovered across 439 OR cases. After implementation, there were 7,454 OR cases with a total of 930 charting discrepancies (12.48 discrepancies per 100 total OR cases; P < 0.0001) discovered across 680 OR cases. While discrepancies increased by 38%, the median review time for the OR analyst per case decreased (P < 0.0001) and the percentage of incidents resolved by the OR analyst increased by 14% while the number of cases requiring additional documentation by the provider decreased by 10%.

CONCLUSION

Implementation of advanced analytics software in the OR significantly increased the number of controlled substance charting discrepancies identified compared to the preimplementation review process while increasing the efficiency of the OR analyst.

摘要

目的

本研究调查了手术室（OR）中高级分析软件解决方案对跟踪和评估受控物质差异的影响。作者假设该软件将增加对这些差异的识别，并提高现有手动流程的效率。

方法

在这项比较实施软件前后数据的评估中，在实施前使用现有的手动流程收集了 50 天的数据，然后是 25 天的新软件适应期，最后是 49 天的实施后审查期。收集的数据包括药物差异总数、OR 分析师审查和协调差异所需的时间、差异类型以及导致提供者审核的差异数量。

结果

在实施分析软件之前，有 7635 例 OR 病例，总共有 674 份图表差异（每 100 例总 OR 病例 8.83 个差异），其中 439 例 OR 病例有差异。实施后，有 7454 例 OR 病例，总共有 930 份图表差异（每 100 例总 OR 病例 12.48 个差异；P < 0.0001），其中 680 例 OR 病例有差异。虽然差异增加了 38%，但 OR 分析师每例病例的审查时间中位数减少（P < 0.0001），OR 分析师解决的事件百分比增加了 14%，而需要提供者额外记录的病例数量减少了 10%。